look at eli lilly attention they're getting because of a positive drug trial there.company like axem get as positive drug trial look -- liz: makes sense to acquire intellectual property because it takes forever and man and woman power to create. >> time and money. liz: drug developments is a fortune a long process that can sometimes end, no, sorry, the fda says no. let me broaden the discussion to markets here. >> yes. liz: federal reserve, three fed heads out saying we're not done with interest rate hikes. does that mean we still have more legs down for this market? >> i think more volatility is ahead but i think the fed becomes less aggressive by the end of the year. doesn't mean they stop hiking rates. the means days of 75 basis point hikes are behind us. from that is true we reached hawkishness by extension as peak inflation. investors view this as worst days behind us and better days ahead. liz: what would you avoid, we always say what would you buy, what do you like very much in this atmosphere? >> companies request heavy amount of debt in the balance sheets in

eli lilly has the best weight lose drug in the world and thermal fisher we have an auto company and afinancial and a drug and we have an engineering company and that portfolio is about as perfect as you can possibly get even with this horrendous environment all right. next up is a tweet from badabing 1960 who asked @ asked @madmoney @jimcramer, disney, ford, sirus, petco pa paypal this is more work. we have an auto company. we have a fintech company, a retailer not doing as well as i'd like but better. we have an entertainment company and believe it or not, this is linked to this this is a satellite radio company that does well if you sell a lot of cars but if you don't, it doesn't do well so we're actually going to get rid of this name and we're going to put in, yes, we're going to go back to eli lilly this will be done monday morning. next up, we have inmid va from omar. >> hey, jim, omar in new york. long-time fan. thank you for what you do for the retail community my top five portfolio holdings are united airlines, ual, apple, aapl, jp morgan choice, jpm, advanced micro devices an

we're getting rid of this and put eli lilly in here. why not? pioneer very, very much and i hope that makes the changes -- i'd make the changes on monday because this is really getting messy and this one i don't know what they own next up is ryan in minnesota ryan >> oh, hey, there, jim it ryan from minnesota i want to say thank you for everything you do and i'm also a member of the cnbc investing club top five holdings for am i diversified. amazon, huntington bank corp, pioneer natural resources, mp materials and danahugh boo-yah. >> boo-yah look, this is about teaching i have a lot of soul sourcing with jeff marks this week because we like the market the market was up. we're trying to do is teach. what are we trying to teach? a company represents fantastic life science growth that amazon is actually amazon web services, also amazon advertising and it's prime and don't forget it's got that thursday night game which is very good by the way and i like those announcers. and m.p. materials you need that those are rare materials, soon we have to get

reporter: but there's optimism. 130,000 square feet of lab space paid for and made available by eli lilly. putting more than 250 people to work and that's just the beginning. >> there's so many talented scientists and students coming out of top universities here. we want to give them opportunities to work here, develop their ideas and maybe turn them into medicines to help people. >> there's more positive news from companies that have struggled recently. netflix and adobe posting better than expected earnings, rewarding their investors. >> if you're not following scott on twitter, you should. always posting tech and business news. @scottbudman. >>> just three weeks until the midterm elections. we'll look at one measure on the ballot that could change how abortion rights are protected in california. >>> the family of george floyd taking action against kanye west after the rapper made controversial comments about floyd's death. what the family is demanding. >>> i'm chief meteorologist jeff ranieri, i'll have the latest on the wildfire season and w thehy >>> we are now three weeks out from t

eli lilly hitting an all of time high the question, can the strength continue let's bring in chart masterrter worth of worth charting hey, carter. >> it's a case of the least bad. we know all sectors are down except energy, of course, and those that are down the least, the obvious ones, utilities, staples. but health care down the least of the other ten that are down let's look at some charts. the first is a simple two panel chart. what you're looking at is the entire health care sector on top as measured by the spider health care etfxlv. on the bottom is relative performance to the market. and those arrows drawn tell the tale it's down, the tech to have, but it's going straight up relative to the s&p nothing new there. there are several stocks that are at 52-week highs and poised to break out look at lily how many stocks in this stock market among the russell 3,000 are at 52-week highs poised to break out? not many lily is one of them. look at merck. exact same setup both exhibiting relative strength the final table is really the most interesting thing what we have is we know that health

now, eli lilly has a drug that is for diabetes and obesity, and david, people are doing that game --ber the game where you check the scrips every week? that's a fool's game the fact is, this maybe the greatest-selling drug of all time i'm putting it up there with lipicor, because you can lose 22 pounds >> that's a lot of weight. >> people who are worried about their weight, you should do -- you add this to the mix, and david, we'll all live to a hundred. >> okay. that makes me wonder about the entitlement programs but okay >> new mexico? hundred. >> a hundred you're more likely on the hundred than anything else, probably >> you like that >> carl mentioned wynn, you saw it there in terms of s&p gainers. >> what do you think about tilman you know, tillman fman fertittas a roughly 6% position in wynn. it's a passive stake of course, that is the way that elon musk began in twitter remember that? remember that? >> you're too much >> which never should have been filed as a g in this case, what i'm hearing is, listen, he's not sure what he's going to do here, but i would point out, mccormic

that study even the most optimistic take on the result it has some effect on the trajectory and eli lilly issued a phase 2 study of a different drug the same idea to go after amyloids and the same thing in effect but not a halting or herself but that change in the decline. the book how and that b model of going after amyloids with antibody approach of the novel idea of going after amyloids like it was a foreign invader using antibody technologies. and win his first paper came out in nature on the cover of nature it was so groundbreaking it actually made the national news and mind you this was not a study done on humans who had alzheimer's. it was a study done on genetically engineered mice who were engineered with these amyloids and they did this experiment on them but it was so groundbreaking some of the investigators at the time actually said this field is figure out and they were going to pivot on the disease. i chronicle and the book of the initial enthusiasm has certainly been dampened if i've explained and even studies that don't have controversy you see the slow effect. again progr

i would've killed for one billionaire to come on the air at the beginning of the year that said eli lillythat could be just fantastic. or just because we go into recession, caterpillar is a changed company and you have all the that federal of the structure money. the only question is, how can caterpillar hand the demand? it reminds me of my own trajector . i didn't have any money i was living in my car and doing everything wrong. i started out learning and discovering and being diligent about this stuf . it's not like betting a bunch of horses which is i what i used to do. there was big pharma in the 80s and i would like to see who had the best drug pipeline. sometimes it was obvious and then i will hold them until the stories came to fruition. i made a lot of money off of a little money. a lot off a little an eye learned. investor funds are great but they will not let you rack up gains. the reason i do my job now is to teach you to become a better investor. it's just about teaching, darn it. maybe you don't know how to be disciplined or do the homework or maybe the whole thing is bewilde

eli lilly has been hired for much of the session on encouraging outlook it shares a type to its obesityn the world of earnings, there have been lower bars and this in the jack mccormick, they were able to beat lower expectations to the tune of about .5%. we continue to watch the rocky road ahead for peloton. it is up 3% now but that is on news that they are cutting even more jobs. we will watch to see the future of that. meanwhile, social media stocks have been under pressure this year. a light of worries about where digital advertising dollars will be in 2023. but today, goldman sachs bullish on pinterest. kriti: everyone trading for that equity story, but we are also waiting for the equity story, a sustainable rally when it comes to the stock market, some to capitulation is the track, but there is already a bit of green on the screen. that is a take of daniel morris. >> we appreciate the one hand that sentiment is bad. no one likes equities, risk, but at the same time, you get a bit of good news and i think you can see some of the price action we have already had. going into the third

eli lilly, it's a little bit bigger than ollie's.lized that lilly's market cap is now $ $315 billion it's line a hundred billion dollars bigger than merck. i don't know how i missed that >> perhaps because you're not trying to take -- >> only trails j&j eli lilly did announce the u.s. food and drug administration's granted fast-track approval for the treatment of adults with obesity or overweight with weight-related comorbidities jim has been talking about this a lot, of course there's this surmount one, two trials, 2,539 participants across the world in many ways. which obviously showed some very positive results they are going to be using for this fast track, the results from two phase 3 clinical trials, as i just said, these that i just referenced jim, you think there's a big market for this drug >> actually, it's interesting how much people want this because this is a delay of one year to get a prescription, so you may have to use it off-label, which means the prescription will not -- the insurance companies will not pay for it b

bi've been through many periods we heard the same thing from j&j and bristle myers, coca-cola and eli lilly. those don't make the investing banking much money and sponsorship unless those companies decide to make acquisitions or break themselves up like j&j. the analysts keep promoting the money losers even as the research directors warning and tell you to stay away. because these are going to be gutted as the economy slows down meanwhile, nobody is championing what actually works. these consumer package names we know with high yields, big buybacks when i went through proctor's quarter this morning, they talked about $3.9 billion. 3.9 billion. i bet those costs would be reduced. at the same time proctor has brand power. they rarely lose business to trade down competitors even in a recession they have an amazing research and development arm with very sophisticated targeting advertising. they won't bring much business to an investing bank for a full year i railed against a richly valued stanc i want to chalk this up to hope, not selfishness. when you get an amazing quarter and so many old pac

break, a look at health care and pharma stocks hitting new highs in today's sessions you've got eli lilly up 2% humana up 1 1/2% and murk up a li 1% >>> welcome back to "power lunch. declining used car prices required them to sell quickly through that inventory to maintain margins let's bring in earle hesterberg. >> thanks for having me. >> brian's phone is going off. >> i got so excitedtalking about cars i saw the astros jersey. >> i don't know how that happened. >> it does and then you just roll with it, earle. has something changed where you've seen used car prices go down and you've had to work with that inventory >> we expected used car prices to go down because they were at all-time highs and quite frankly those were unsustainable so we've been preparing for this but when used car market prices decline, we keep a very lean inventory of about 30 days we have to flush that retail out quickly so we can rebase our price level at the latest prices we had to do a bit of that last quarter and we're pretty clean again, i think >> we're talking to a lot of ceos across industries about lookin

moment what you would be doing in april of 2015, 2016, i would have said, oh, i will be retiring from eli lilly and company. that has been the longest stretch of my work. i was involved at the top of that company and enjoying it and completely absorbed in it. and my life changed completely three times since then. i tell the students, sure, have a plan, but life will bring you. given your talents and your purdue degree, life will bring you opportunities you did not think about. some of them might be the right ones. so how is that for ducking your question? beth: perfect. we will look forward to following your work wherever you go next, but i think at this point i can turn to the audience . we have a lot of folks eager to ask you questions. ok. see if we can bring a microphone in here. >> my name is donald and i am a retired corporate lawyer, and i hear a lot about threat to democracies around the world and perhaps in this country, so i am wondering about how your students learn about our democracy. you answered my question by saying that you introduced a civics course for freshmen recently. gov.

. >> next buy is eli lilly, shares hitting an all-time high in today's trading and set to report third before the pail. this is your pharma play, gina, and it's doing well, may even have bprosecutor prospects next year tell us about it >> absolutely. this is actually one where the analysts have been revising down upcomings, because it's a tough -- it's been a tough quarter. this is the first full quarter when their lug cancer drug has had to kind of compete if the generation market, but if you look next year, one of the biggest blockbuster drugs that's coming out on the market is the big weight loss drug that's coming up against ozempic and the other weight loss drugs. and everyone is expecting the tests have been extraordinary. and these are very, very profitable drugs so, the expectations are really, really strong, even for next year and they've already done really well this year >> and all-time high wecht been able to say that very often about many stocks in recent months. final buy is humana, also hitting an all-time high today and reports before the pbell on wednesday. you like th

. >> right >> caller: so thank you, jim my question, i own the club stock eli lilly for its weight lossngioro and the other great drugs it has in its pipeline but i'm wondering about another company. there's two, actually, that are making weight loss drugs one is novo nordisk. and i'm wondering if we should increate our weighting in the weight loss opportunity. >> i don't like other aspects of novo's business. and remember, they don't have the approval port weight loss. i think it's going to get it i'm on lyrica. i own lyrica and it gains weight, i need this drug to take the weight off. thank you for being a member of the club thank you for understanding what the heck we really do, which is teach. because that's what i'd be doing if i weren't doing the club. but there were only be like 300 people we're finally get progress in the war on inflation and progress is this market's most important product. big blue flashed some big green after earnings so what should you make of ibm now? i'll give you my take. then fedex flashed a warning last quarter is it time to reevaluate the transports i'

recently eli lilly issued data from a phase two study of a different drug, same idea, go after amyloid and same thing, an effect on the client but not a halting non-reversal but a change in the rate of decline. .. antibody approach involved in other scientific risk taker who came up with this id an idea of going after amyloid like a foreign invader using anybody technologies. when his first paper came out in the cover of nature it was so groundbreaking it made the national news and this was not a study done in humans who had alzheimer's but genetically engineered mice who produce the amyloid. it was so groundbreaking that some investigators at the time said this feels figured out. they were going to pivot. i chronicle in the book how the initial enthusiasm was dampened. even studies not steeped in controversy you see the slow effect but not the definitive effect. progress is occurring but we live with this disease and that a key theme, we need to live with cognitive impairment, that present sonorous opportunities and challenges. >> host: drug therapy has the same famous tech curve for

, a name weave talked about for years, valuations still reasonable, earnings in november 4'd and eli lillyem to be coming around the fact that elittly is the best big-cap pharma name out there. yes this, space is still investable at this level. >> jim cramer says it all the time there's always a bull market somewhere and we're in a fast i bear market. that thing is the best looking chart i've ever seen >> in your life. >> remember, that was with lisa, had a little thing the worst looking chart ever. >> like lumor. >> retail. >> the triangle of death >> yeah. >> all right coming up, the market is broken. that's the word from jim bianco who says why and stocks holding up despite the market volatility can you build a foundation with these builder names? stick around o.y"ilbeacinl bk tw ♪ in any business, you ride the line between numbers and people. what's right for the business and what's best for everyone who depends on it. solving today's challenges while creating future opportunities. it takes balance. cla - cpas, consultants, and wealth advisors. we'll get you there. >>> welcome back to

that's another great example and we have names like eli lilly that are in there, t-mobile with 30% growth and yet it's priced at 23 times. it's great to be boring again. and we're seeing opportunities in those boring areas. and it's kind of fun to go back to some oldtime stock selection in those groups. >> that's it, don haher, t-mobie starbucks, jeff crumbleman, boring is the new red hot. jeff, thank you. j you're not boring. thank you. >>> on deck, climate companies and venture capitalists are gathered in seattle to address the challenge of net zero emissions. the surmt immit is hosted by hi energy group >>> plus, business on the ballot believe it or not, china may be a huge issue for voters in ohio. we'll explain how, coming up - oh, the stock market is doing that fun thing again. news from the future: you're going to live through that about 10 more times! (laughs) no stress. i just discovered yieldstreet. they vet investments that don't ride the stock market rollercoaster. - [narrator] yieldstreet: private market investing. - oh, the stock market is doing that fun thing again. news fr

pfizer's a covid infused juggernaut and our favorite trust stock eli lilly is best in show with its terrific diabetes franchise and by the way doubles as the world's safest i think but hasn't been approved for full use weight loss drug yeah that's going to be an amazing drug given how obesity is among the biggest killers. drug's a godsend how about the leadership group we don't spend a lot of time pondering the lasting psychological damage from the pandemic which kept us locked up doing nothing. now that covid's receded everybody's eager to travel again, see the world, catch up with friends, go to weddings and we've got more time to travel thanks to so many businesses embracing a work from home model. and that's why i like united air and delta. it's why i think they got a raw deal the other day that's why i said boeing last night is going to work these are misunderstood worth buying stocks. fourth a huge conventional war going in ukraine you can't fight a war without, yes, weapons that means the strength in lockheed martin, northrop grumman and my favorite l-3 harris every time one of these

optimistic take on their results are that it has some effect on the trajectory of decline and recently eli lillyissued data from a phase 2 study of a different drug that had the same idea, go go after amyloid and the same thing and effect on declinebut not a halting, not a reversal a change . i chronicle in the book how that model of going after amyloid's with an antibiotic approach actually involved another just scientific risk taker named gail schein who came up with this novel idea of going after amyloid's like it was a foreign invader using anti-body technologies. and when his first peeper paper came out in nature, it was so groundbreaking it actually made the national news and mind you this was not a study done in humans who had alzheimer's, it was a study done on genetically engineered mice that had been engineered to produce pr amyloid's but it was so groundbreaking that some investigators at the time said this feels figured out and they're going to pivot to other diseases. i chronicle in the book how the initial enthusiasm has certainly been dampened as i've explained. even some would ar